Refusal of the request- The U.S. Food and Drug Administration (FDA) had to deliver this message to Elon Musk’s brain implant company, Neuralink, after it requested permission to conduct human trials.
In addition, it seems improbable that Neuralink will receive approval in the near future, at least not within any of the timeframes Musk has previously mentioned.
Reuters has released a new report containing the news that the FDA has denied Neuralink’s application (Opens in a new tab). More than a half-dozen current and former employees shared details of the rejection, which occurred approximately a year ago, with the news organization. The FDA’s denial was not previously made public.Information Guide Nigeria
Musk has repeatedly described his grand vision for Neuralink over the years. Musk claims that once a Neuralink chip is implanted in a patient’s brain, it could restore sight to the blind and enable paralyzed individuals to walk again. Musk has gone even further, imagining that the chip could record people’s memories so that they can recall moments they might otherwise forget.NYSC Portal
Other Top Stories:
- Twitter Blue is now available in 20 new European countries
- TikTok sets 60-minute daily screen time limit for under-18s
- Windows 12 might have just been leaked by Microsoft and Intel
- OpenAI opens ChatGPT floodgates with dirt-cheap API
According to sources, the FDA denied Neuralink’s request to begin human trials due to “dozens of issues the company must address.” Some of the FDA’s safety concerns include the potential for the device’s wires to “migrate” and damage other areas of the brain, potential issues with the lithium battery in the device, and whether a surgical procedure to remove the device would cause brain tissue damage to the patient.
Investigations into whether Neuralink violated animal welfare laws while attempting to expedite its development are likely to amplify these safety concerns. Approximately 1,500 monkeys, pigs, and mice have been killed in Neuralink testing since 2018, according to a previous Reuters report(Opens in a new tab).
“Neuralink doesn’t appear to have the mindset and experience that’s needed to get this to market anytime soon,” a former program director for neural engineering in the U.S. National Institutes of Health (NIH) told Reuters.JAMB Result
Check JAMB Result
Check and Confirm: How much is Dollar to Naira
